HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Praxis Precision Medicine (NASDAQ:PRAX) and maintained a price target of $120.
September 03, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Praxis Precision Medicine, maintaining a $120 price target. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100